PHAR · Pharming Group N.V. · Documents
$12.13
-0.13 (-1.06%)
At close · Oct 29
Return incl. dividend (before tax)
Q3 2026 earnings call transcript
Market Cap
$859.95M
Shares
70.78M
Volume · Oct 29
12.43K
Avg daily vol (3M)
25.01K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 6-K | Pharming Group N.V. reported third-quarter 2026 revenue up 21% to US$117.6 million and tightened 2026 guidance to between US$380.0 million and US$390.0 million. Joenja revenue rose 58% to US$23.8 million, and CVID Phase II results are expected in November 2026. | 2026-10-27 | — | |
| 6-K | Pharming Group N.V. expects third quarter 2026 revenues of approximately US$117.6 million, up approximately 21% year-on-year, and operating expenses of approximately US$74.6 million. It tightened 2026 revenue guidance to US$380 million - US$390 million; results are set for October 27, 2026. | 2026-10-22 | — | |
| 6-K | Pharming Group N.V. reported positive Phase II topline data for leniolisib in genetic PIDs: mean spleen volume fell 26.4%, index lymph node lesion size fell 33.7%, and mean DLCO rose 8.0% among 7 participants with impaired gas exchange. | 2026-10-14 | — | |
| 6-K | Pharming announced that Fabrice Chouraqui will immediately step down as CEO and Executive Director due to strategic differences with the Board. Leverne Marsh and Kenneth Lynard became Interim Co-CEOs while the Board searches for a permanent successor. | 2026-09-29 | — | |
| 6-K | Pharming Group N.V. announced U.S. Food and Drug Administration acceptance and Priority Review of its sNDA for lower Joenja® doses for pediatric APDS patients, with a January 30, 2027 PDUFA target action date. | 2026-09-25 | — | |
| 6-K | Pharming Group N.V. announced positive Phase II topline data for leniolisib in 13 patients with genetically defined PIDs, including a mean 26.4% spleen volume reduction, and expects separate CVID Phase II topline results in Q4 2026. | 2026-09-22 | — | |
| Investor Event Transcript | — | 2026-09-14 | 2026-09-30 | |
| 6-K | — | 2026-09-11 | — | |
| 6-K | — | 2026-08-13 | — | |
| 6-K | — | 2026-07-30 | — | |
| 6-K | — | 2026-06-04 | — | |
| 6-K | — | 2026-05-28 | — | |
| 6-K | — | 2026-05-22 | — | |
| 6-K | — | 2026-05-07 | — | |
| 6-K | — | 2026-05-07 | — | |
| 6-K | — | 2026-04-16 | — | |
| 20-F/A | — | 2026-04-13 | 2025-12-31 | |
| 20-F | — | 2026-04-02 | 2025-12-31 | |
| 6-K | — | 2026-04-02 | — | |
| 6-K | — | 2026-03-27 | — | |
| 6-K | — | 2026-03-24 | — | |
| 6-K | — | 2026-03-12 | — | |
| 6-K | — | 2026-02-03 | — | |
| 6-K | — | 2026-02-02 | 2026-02-01 | |
| 6-K | — | 2026-01-08 | — | |
| 6-K | — | 2025-11-06 | — | |
| 6-K | — | 2025-10-22 | 2025-10-20 | |
| 6-K | — | 2025-10-06 | — | |
| 6-K | — | 2025-10-01 | — | |
| 6-K | — | 2025-09-10 | — | |
| 6-K | — | 2025-09-02 | — | |
| 6-K | — | 2025-07-31 | — | |
| 6-K | — | 2025-06-24 | — | |
| 6-K | — | 2025-06-11 | — | |
| 6-K | — | 2025-05-08 | — | |
| 6-K | — | 2025-04-30 | — | |
| 6-K | — | 2025-04-25 | — | |
| 6-K | — | 2025-04-23 | — | |
| 6-K | — | 2025-04-03 | — | |
| 20-F | — | 2025-04-03 | 2024-12-31 | |
| 6-K | — | 2025-03-20 | — | |
| 6-K | — | 2025-03-13 | — | |
| 6-K | — | 2025-03-04 | — | |
| 6-K | — | 2025-02-20 | — | |
| 6-K | — | 2025-02-07 | — | |
| 6-K | — | 2025-01-21 | — | |
| 6-K | — | 2025-01-21 | — | |
| 6-K | — | 2024-12-16 | 2024-12-15 | |
| 6-K | — | 2024-12-11 | — | |
| 6-K | — | 2024-10-24 | — |
Showing 1–50 of 129 filings